Forgotten public health impacts of cancer – an overview

1. World Health Organization (WHO). Health in 2015: from MDGs, Millennium Development Goals to SDGs, Sustainable Development Goals. Geneva: WHO; 2015.Search in Google Scholar

2. Ferrando-Climent L, Rodriguez-Mozaz S, Barceló D. Incidence of anticancer drugs in an aquatic urban system: from hospital effluents through urban wastewater to natural environment. Environ Pollut 2014;193:216-23. doi: 10.1016/j.envpol.2014.07.00210.1016/j.envpol.2014.07.00225062279Open DOISearch in Google Scholar

3. Ma X, Yu H. Global burden of cancer. Yale J Biol Med 2006;79:85-94. PMCID: PMC1994799Search in Google Scholar

4. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108. doi: 10.3322/ canjclin.55.2.7410.3322/canjclin.55.2.7415761078Open DOISearch in Google Scholar

5. Boffetta P, Nyberg F. Contribution of environmental factors to cancer risk. Br Med Bull 2003;68:71-94. doi: 10.1093/ bmp/ldg02310.1093/bmp/ldg02314757710Open DOISearch in Google Scholar

6. Takala J. Eliminating occupational cancer. Ind Health 2015;53:307-9. doi: 10.2486/indhealth.53-30710.2486/indhealth.53-307455106026377441Open DOISearch in Google Scholar

7. Takala J, Hämäläinen P, Saarela KL, Yun LY, Manickam K, Jin TW, Heng P, Tjong C, Kheng LG, Lim S, Lin GS. Global estimates of the burden of injury and illness at work in 2012. J Occup Environ Hyg 2014;11 :326-37. doi: 10.1080/15459624.2013.86313110.1080/15459624.2013.863131400385924219404Open DOISearch in Google Scholar

8. Takala J. Eliminating occupational cancer in Europe and globally. SSRN Electron J 2015. doi: 10.2139/ssrn.268109210.2139/ssrn.2681092Search in Google Scholar

9. Ladeira C, Viegas S, Pádua M, Gomes M, Carolino E, Gomes MC, Brito M. Assessment of genotoxic effects in nurses handling cytostatic drugs. J Toxicol Environ Health A 2014;77:879-87. doi: 10.1080/15287394.2014.91015810.1080/15287394.2014.91015825072720Open DOISearch in Google Scholar

10. Rushton L, Hutchings S, Brown T. The burden of cancer at work: estimation as the first step to prevention. Occup Environ Med 2008;65:789-800. doi: 10.1136/ oem.2007.03700210.1136/oem.2007.03700218079154Search in Google Scholar

11. Park E-K, Takahashi K, Jiang Y, Movahed M, Kameda T. Elimination of asbestos use and asbestos-related diseases: An unfinished story. Cancer Sci 2012;103:1751-5. doi: 1 0.1111/j.1349-7006.2012.02366.x10.1111/j.1349-7006.2012.02366.x765929022726320Search in Google Scholar

12. Stayner L, Welch LS, Lemen R. The worldwide pandemic of asbestos-related diseases. Annu Rev Public Health 2013; 34 : 205 - 16. doi : 10.1146/annurev-publhealth-031811-12470410.1146/annurev-publhealth-031811-12470423297667Open DOISearch in Google Scholar

13. Karaer F. Environmental pollution and carcinogenic risk. J Environ Pathol Toxicol Oncol 1996;15:105-13. PMID: 9216793Search in Google Scholar

14. National Research Council (NRC). Carcinogens and Anticarcinogens in the Human Diet: A Comparison of Naturally Occurring and Synthetic Substances. Washington (DC): National Academies Press; 1996. doi: 10.17226/515010.17226/5150Open DOISearch in Google Scholar

15. American Cancer Society (ACS). Global Cancer Facts & Figures. 3rd ed. Atlanta (GA): American Cancer Society Inc.; 2015.Search in Google Scholar

16. American Cancer Society (ACS). Global Cancer Facts & Figures. 2nd ed. Atlanta (GA): American Cancer Society Inc.; 2011.Search in Google Scholar

17. Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: a populationbased cost analysis. Lancet Oncol 2013;14:1165-74. doi: 10.1016/S1470-2045(13)70442-X10.1016/S1470-2045(13)70442-XOpen DOISearch in Google Scholar

18. European Chemicals Agency (ECHA). Guidance on the Preparation of an Application for Authorisation. Helsinki: ECHA; 2011.Search in Google Scholar

19. Burgaz S, Karahalil B, Bayrak P, Taşkin L, Yavuzaslan F, Bökesoy I, Anzion RB, Bos RP, Platin N. Urinary cyclophosphamide excretion and micronuclei frequencies in peripheral lymphocytes and in exfoliated buccal epithelial cells of nurses handling antineoplastics. Mutat Res 1999;439:97-104. doi: 10.1016/S1383-5718(98)00180-610.1016/S1383-5718(98)00180-6Open DOISearch in Google Scholar

20. Sessink PJ, Bos RP. Drugs hazardous to healthcare workers. Evaluation of methods for monitoring occupational exposure to cytostatic drugs. Drug Saf 1999;20:347-59. PMID: 1023058210.2165/00002018-199920040-00004Search in Google Scholar

21. Bouraoui S, Brahem A, Tabka F, Mrizek N, Saad A, Elghezal H. Assessment of chromosomal aberrations, micronuclei and proliferation rate index in peripheral lymphocytes from Tunisian nurses handling cytotoxic drugs. Environ Toxicol Pharmacol 2011;31:250-7. doi: 10.1016/j.etap.2010.11.00410.1016/j.etap.2010.11.004Open DOISearch in Google Scholar

22. Gulten T, Evke E, Ercan I, Evrensel T, Kurt E, Manavoglu O. Lack of genotoxicity in medical oncology nurses handling antineoplastic drugs: effect of work environment and protective equipment. Work 2011;39:485-9. doi: 10.3233/ WOR-2011-119810.3233/WOR-2011-1198Open DOISearch in Google Scholar

23. Buschini A, Villarini M, Feretti D, Mussi F, Dominici L, Zerbini I, Moretti M, Ceretti E, Bonfiglioli R, Carrieri M, Gelatti U, Rossi C, Monarca S, Poli P. Multicentre study for the evaluation of mutagenic/carcinogenic risk in nurses exposed to antineoplastic drugs: assessment of DNA damage. Occup Environ Med 2013;70:789-94. doi: 10.1136/oemed-2013-10147510.1136/oemed-2013-101475Open DOISearch in Google Scholar

24. Toolaram AP, Kümmerer K, Schneider M. Environmental risk assessment of anti-cancer drugs and their transformation products: A focus on their genotoxicity characterization-state of knowledge and short comings. Mutat Res - Rev Mutat Res 2014;760:18-35. doi: 10.1016/j.mrrev.2014.02.00110.1016/j.mrrev.2014.02.001Open DOISearch in Google Scholar

25. Fučić A, Jazbec A, Mijić A, Šešo-Šimić D, Tomek R. Cytogenetic consequences after occupational exposure to antineoplastic drugs. Mutat Res 1998;416:59-66. doi: 10.1016/S1383-5718(98)00084-910.1016/S1383-5718(98)00084-9Open DOISearch in Google Scholar

26. Villarini M, Dominici L, Fatigoni C, Muzi G, Monarca S, Moretti M. Biological effect monitoring in peripheral blood lymphocytes from subjects occupationally exposed to antineoplastic drugs: assessment of micronuclei frequency. J Occup Health 2012;54:405-15. doi: 10.1539/joh.12-0038-OA10.1539/joh.12-0038-OA22986622Open DOISearch in Google Scholar

27. Kopjar N, Želježić D, Kašuba V, Rozgaj R. Antineoplastični lijekovi kao čimbenik rizika u radnom okolišu: mehanizmi djelovanja na razini stanice i pregled metoda za otkrivanje njihovih genotoksičnih učinaka [Antineoplastic drugs as a potential risk factor in occupational settings: mechanisms of action at the cell level, genotoxic effects, and their detection using different biomarkers, in Croatian]. Arh Hig Rada Toksikol 2010;61:121-46. doi: 10.2478/10004-1254-61- 2010-202510.2478/10004-1254-61-2010-2025Open DOISearch in Google Scholar

28. National Institute for Occupational Safety and Health (NIOSH). NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016. Cincinnati, (OH): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention NIOSH; 2016.Search in Google Scholar

29. Gerić M, Gajski G, Garaj-Vrhovac V. γ-H2AX as a biomarker for DNA double-strand breaks in ecotoxicology. Ecotoxicol Environ Saf 2014;105:13-21. doi: 10.1016/j. ecoenv.2014.03.03510.1016/j.ecoenv.2014.03.035Open DOISearch in Google Scholar

30. Moen MD, McKeage K, Plosker GL, Siddiqui MAA. Imatinib: a review of its use in chronic myeloid leukaemia. Drugs 2007;67:299-320. PMID: 1728409110.2165/00003495-200767020-00010Search in Google Scholar

31. Mani S, Ratain MJ. Promising new agents in oncologic treatment. Curr Opin Oncol 1996;8:525-34. PMID: 897147310.1097/00001622-199611000-00013Search in Google Scholar

32. Novak M, Žegura B, Nunić J, Gajski G, Gerić M, Garaj- Vrhovac V, Filipič M. Assessment of the genotoxicity of the tyrosine kinase inhibitor imatinib mesylate in cultured fish and human cells. Mutat Res Toxicol Environ Mutagen 2017;814:14-21. doi: 10.1016/j.mrgentox.2016.12.00210.1016/j.mrgentox.2016.12.002Open DOISearch in Google Scholar

33. Arezes PM. Occupational safety and hygiene III : selected extended and revised contributions from the International Symposium on Safety and Hygiene; 12-13 February 2015. Guimarães, Portugal 2015. London: Taylor and Francis Group; 2015.Search in Google Scholar

34. Jackson MA, Stack HF, Waters MD. Genetic activity profiles of anticancer drugs. Mutat Res 1996;355:171-208. PMID: 878158310.1016/0027-5107(96)00028-0Search in Google Scholar

35. Rombaldi F, Cassini C, Salvador M, Saffi J, Erdtmann B. Occupational risk assessment of genotoxicity and oxidative stress in workers handling anti-neoplastic drugs during a working week. Mutagenesis 2008;24:143-8. doi: 10.1093/ mutage/gen06010.1093/mutage/gen06019011124Search in Google Scholar

36. Connor TH. Hazardous anticancer drugs in health care: environmental exposure assessment. Ann N Y Acad Sci 2006;1076:615-23. doi: 10.1196/annals.1371.02110.1196/annals.1371.02117119238Open DOISearch in Google Scholar

37. Kopjar N, Milas I, Garaj-Vrhovac V, Gamulin M. Alkaline comet assay study with breast cancer patients: evaluation of baseline and chemotherapy-induced DNA damage in nontarget cells. Clin Exp Med 2006;6:177-90. doi: 10.1007/ s10238-006-0113-810.1007/s10238-006-0113-817191110Open DOISearch in Google Scholar

38. Zounkova R, Kovalova L, Blaha L, Dott W. Ecotoxicity and genotoxicity assessment of cytotoxic antineoplastic drugs and their metabolites. Chemosphere 2010;81:253-60. doi: 10.1016/j.chemosphere.2010.06.02910.1016/j.chemosphere.2010.06.02920624627Open DOISearch in Google Scholar

39. Gajski G, Gerić M, Domijan A-M, Garaj-Vrhovac V. Combined cyto/genotoxic activity of a selected antineoplastic drug mixture in human circulating blood cells. Chemosphere 2016;165:529-38. doi: 10.1016/j.chemosphere.2016.09.05810.1016/j.chemosphere.2016.09.05827681109Open DOISearch in Google Scholar

40. Musak L, Smerhovsky Z, Halasova E, Osina O, Letkova L, Vodickova L, Polakova V, Buchancova J, Hemminki K, Vodicka P. Chromosomal damage among medical staff occupationally exposed to volatile anesthetics, antineoplastic drugs, and formaldehyde. Scand J Work Environ Health 2013;39:618-30. doi: 10.5271/sjweh.335810.5271/sjweh.335823525098Open DOISearch in Google Scholar

41. Boffetta P, Kaldor JM. Secondary malignancies following cancer chemotherapy. Acta Oncol 1994;33:591-8. doi: 10.3109/0284186940912176710.3109/028418694091217677946433Search in Google Scholar

42. Vega-Stromberg T. Chemotherapy-induced secondary malignancies. J Infus Nurs 2003;26:353-61. PMID: 1462417510.1097/00129804-200311000-0000414624175Search in Google Scholar

43. Ng AK, Kenney LB, Gilbert ES, Travis LB. Secondary malignancies across the age spectrum. Semin Radiat Oncol 2010;20:67-78. doi: 10.1016/j.semradonc.2009.09.00210.1016/j.semradonc.2009.09.002385775819959033Open DOISearch in Google Scholar

44. Rodriguez-Mozaz S, Weinberg HS. Meeting report: pharmaceuticals in water-an interdisciplinary approach to a public health challenge. Environ Health Perspect 2010;118:1016-20. doi: 10.1289/ehp.090153210.1289/ehp.0901532292090120338860Search in Google Scholar

45. Kosjek T, Heath E. Occurrence, fate and determination of cytostatic pharmaceuticals in the environment. TrAC - Trends Anal Chem 2011;30:1065-87. doi: 10.1016/j.trac.2011.04.00710.1016/j.trac.2011.04.007Open DOISearch in Google Scholar

46. Besse JP, Latour JF, Garric J. Anticancer drugs in surface waters. What can we say about the occurrence and environmental significance of cytotoxic, cytostatic and endocrine therapy drugs? Environ Int 2012;39:73-86. doi: 10.1016/j.envint.2011.10.00210.1016/j.envint.2011.10.00222208745Open DOISearch in Google Scholar

47. Deblonde T, Hartemann P. Environmental impact of medical prescriptions: Assessing the risks and hazards of persistence, bioaccumulation and toxicity of pharmaceuticals. Public Health 2013;127:312-7. doi: 10.1016/j.puhe.2013.01.02610.1016/j.puhe.2013.01.02623497754Open DOISearch in Google Scholar

48. Zhang J, Chang VWC, Giannis A, Wang J-Y. Removal of cytostatic drugs from aquatic environment: a review. Sci Total Environ 2013;445-446:281-98. doi: 10.1016/j. scitotenv.2012.12.06110.1016/j.scitotenv.2012.12.06123337605Open DOISearch in Google Scholar

49. Hughes SR, Kay P, Brown LE. Global synthesis and critical evaluation of pharmaceutical data sets collected from river systems. Environ Sci Technol 2013;47:661-77. doi: 10.1021/ es303014810.1021/es3030148363677923227929Open DOISearch in Google Scholar

50. Elersek T, Milavec S, Korošec M, Brezovsek P, Negreira N, Zonja B, de Alda ML, Barceló D, Heath E, Ščančar J, Filipič M. Toxicity of the mixture of selected antineoplastic drugs against aquatic primary producers. Environ Sci Pollut Res Int 2016;23:14780-90. doi: 10.1007/s11356-015-6005-210.1007/s11356-015-6005-226755176Open DOISearch in Google Scholar

51. Booker V, Halsall C, Llewellyn N, Johnson A, Williams R. Prioritising anticancer drugs for environmental monitoring and risk assessment purposes. Sci Total Environ 2014;473- 474:159-70. doi: 10.1016/j.scitotenv.2013.11.14510.1016/j.scitotenv.2013.11.14524369294Open DOISearch in Google Scholar

52. Gajski G, Gerić M, Žegura B, Novak M, Nunić J, Bajrektarević D, Garaj-Vrhovac V, Filipič M. Genotoxic potential of selected cytostatic drugs in human and zebrafish cells. Environ Sci Pollut Res 2016;23:14739-50. doi: 10.1007/s11356-015-4592-610.1007/s11356-015-4592-625943512Open DOISearch in Google Scholar

53. Johnson CA, Jürgens DM, Williams JR, Kummerer K, Kortenkamp A, Sumpter PJ. Do cytotoxic chemotherapy drugs discharged into rivers pose a risk to the environment and human health? An overview and UK case study. J Hydrol 2008;348:167-75. doi: 10.1016/J.JHYDROL.2007.09.05410.1016/j.jhydrol.2007.09.054Open DOISearch in Google Scholar

54. Rowney NC, Johnson AC, Williams RJ. Cytotoxic drugs in drinking water: a prediction and risk assessment exercise for the Thames catchment in the United Kingdom. Environ Toxicol Chem 2009;28:2733-43. doi: 10.1897/09-067.110.1897/09-067.119691418Open DOISearch in Google Scholar

55. Hernando MD, Mezcua M, Fernández-Alba AR, Barceló D. Environmental risk assessment of pharmaceutical residues in wastewater effluents, surface waters and sediments. Talanta 2006;69:334-42. doi: 10.1016/j.talanta.2005.09.03710.1016/j.talanta.2005.09.03718970571Open DOISearch in Google Scholar

56. Jones OA, Lester JN, Voulvoulis N. Pharmaceuticals: a threat to drinking water? Trends Biotechnol 2005;23:163-7. doi: 10.1016/j.tibtech.2005.02.00110.1016/j.tibtech.2005.02.00115780706Open DOISearch in Google Scholar

57. Castiglioni S, Bagnati R, Calamari D, Fanelli R, Zuccato E. A multiresidue analytical method using solid-phase extraction and high-pressure liquid chromatography tandem mass spectrometry to measure pharmaceuticals of different therapeutic classes in urban wastewaters. J Chromatogr A 2005;1092:206-15. doi: 10.1016/j.chroma.2005.07.01210.1016/j.chroma.2005.07.01216199227Open DOISearch in Google Scholar

58. Rabii FW, Segura PA, Fayad PB, Sauvé S. Determination of six chemotherapeutic agents in municipal wastewater using online solid-phase extraction coupled to liquid chromatography-tandem mass spectrometry. Sci Total Environ 2014;487:792-800. doi: 10.1016/j.scitotenv.2013.12.05010.1016/j.scitotenv.2013.12.05024388503Open DOISearch in Google Scholar

59. Martín J, Camacho-Muñoz D, Santos JL, Aparicio I, Alonso E. Occurrence and ecotoxicological risk assessment of 14 cytostatic drugs in wastewater. Water Air Soil Pollut 2014;225:1896. doi: 10.1007/s11270-014-1896-y10.1007/s11270-014-1896-yOpen DOISearch in Google Scholar

60. Gómez-Canela C, Ventura F, Caixach J, Lacorte S. Occurrence of cytostatic compounds in hospital effluents and wastewaters, determined by liquid chromatography coupled to high-resolution mass spectrometry. Anal Bioanal Chem 2014;406:3801-14. doi: 10.1007/s00216-014-7805-910.1007/s00216-014-7805-924825763Open DOISearch in Google Scholar

61. Gómez-Canela C, Cortés-Francisco N, Oliva X, Pujol C, Ventura F, Lacorte S, Caixach J. Occurrence of cyclophosphamide and epirubicin in wastewaters by direct injection analysis-liquid chromatography-high-resolution mass spectrometry. Environ Sci Pollut Res 2012;19:3210-8. doi: 10.1007/s11356-012-0826-z10.1007/s11356-012-0826-z22382696Search in Google Scholar

62. Yin J, Yang Y, Li K, Zhang J, Shao B. Analysis of anticancer drugs in sewage water by selective SPE and UPLC-ESI-MSMS. J Chromatogr Sci 2010;48:781-9. doi: 10.1093/chromsci/48.10.78110.1093/chromsci/48.10.78121044406Open DOISearch in Google Scholar

63. Lambert JC, Lipscomb JC. Mode of action as a determining factor in additivity models for chemical mixture risk assessment. Regul Toxicol Pharmacol 2007;49:183-94. doi: 10.1016/j.yrtph.2007.07.00210.1016/j.yrtph.2007.07.00217804132Open DOISearch in Google Scholar

64. Brain RA, Johnson DJ, Richards SM, Hanson ML, Sanderson H, Lam MW, Young C, Mabury SA, Sibley PK, Solomon KR. Microcosm evaluation of the effects of an eight pharmaceutical mixture to the aquatic macrophytes Lemna gibba and Myriophyllum sibiricum. Aquat Toxicol 2004;70:23-40. doi: 10.1016/j.aquatox.2004.06.01110.1016/j.aquatox.2004.06.01115451605Open DOISearch in Google Scholar

65. Silva E, Rajapakse N, Kortenkamp A. Something from “nothing” - eight weak estrogenic chemicals combined at concentrations below NOECs produce significant mixture effects. Environ Sci Technol 2002;36:1751-6. doi: 10.1021/es010122710.1021/es010122711993873Open DOISearch in Google Scholar

66. Gajski G, Ladeira C, Gerić M, Garaj-Vrhovac V, Viegas S. Genotoxicity assessment of a selected cytostatic drug mixture in human lymphocytes: a study based on concentrations relevant for occupational exposure. Environ Res 2018;161:26-34. doi: 10.1016/j.envres.2017.10.04410.1016/j.envres.2017.10.04429100207Open DOISearch in Google Scholar

67. Mater N, Geret F, Castillo L, Faucet-Marquis V, Albasi C, Pfohl-Leszkowicz A. In vitro tests aiding ecological risk assessment of ciprofloxacin, tamoxifen and cyclophosphamide in range of concentrations released in hospital wastewater and surface water. Environ Int 2014;63:191-200. doi: 10.1016/j.envint.2013.11.01110.1016/j.envint.2013.11.01124317225Open DOISearch in Google Scholar

68. Brezovšek P, Eleršek T, Filipič M. Toxicities of four antineoplastic drugs and their binary mixtures tested on the green alga Pseudokirchneriella subcapitata and the cyanobacterium Synechococcus leopoliensis. Water Res 2014;52:168-77. doi: 10.1016/j.watres.2014.01.00710.1016/j.watres.2014.01.00724472702Open DOISearch in Google Scholar

69. Novak M, Žegura B, Modic B, Heath E, Filipič M. Cytotoxicity and genotoxicity of anticancer drug residues and their mixtures in experimental model with zebrafish liver cells. Sci Total Environ 2017;601-602:293-300. doi: 10.1016/j.scitotenv.2017.05.11510.1016/j.scitotenv.2017.05.115Open DOISearch in Google Scholar

70. Kovács R, Csenki Z, Bakos K, Urbányi B, Horváth Á, Garaj- Vrhovac V, Gajski G, Gerić M, Negreira N, López de Alda M, Barceló D, Heath E, Kosjek T, Žegura B, Novak M, Zajc I, Baebler Š, Rotter A, Ramšak Ž, Filipič M. Assessment of toxicity and genotoxicity of low doses of 5-fluorouracil in zebrafish (Danio rerio) two-generation study. Water Res 2015;77:201-12. doi: 10.1016/j.watres.2015.03.02510.1016/j.watres.2015.03.025Open DOISearch in Google Scholar

71. Custódio JB, Dinis TC, Almeida LM, Madeira VM. Tamoxifen and hydroxytamoxifen as intramembraneous inhibitors of lipid peroxidation. Evidence for peroxyl radical scavenging activity. Biochem Pharmacol 1994;47:1989-98. doi: 10.1016/0006-2952(94)90073-610.1016/0006-2952(94)90073-6Open DOISearch in Google Scholar

72. Kiffmeyer T, Götze H-J, Jursch M, Lüders U. Trace enrichment, chromatographic separation and biodegradation of cytostatic compounds in surface water. Fresenius J Anal Chem 1998;361:185-91. doi: 10.1007/s00216005085910.1007/s002160050859Open DOISearch in Google Scholar

73. Winiwarter V, Haidvogl G, Barben D, Contin M, Cutura M, Domany B, Dorondel S, Egner H, Gajski G, Garcia-Santos G, Gueorguiev T, Hartl M, Hein T, Hudecz F, Ivan O, Jelen I, Jungmeier M, Kopliku B, Laci S, Lenhardt M, Tamáska MD, Mihalca A, Miho A, Papp L, Petrovic A, Pont D, Pop A-M, Popova J, Sandu C, Sendzimir J, Šmid Hribar M, Stoica G, Stöglehner G, Tabakovic M, Terzic A, Torkar G, Žlender V, Zojer H. Danube: Future White Paper on Integrated Sustainable Development of the Danube River Basin. A research community-based White Paper on research and capacity building needs, challenges and opportunities for the development of the sustainability-oriented knowledge society of the Danube River Basin. Alpen-Adria-Universität Klagenfurt Wien Graz & University of Natural Resources and Life Sciences, Vienna; 2015.Search in Google Scholar

74. EUR-Lex. Directive 2004/37/EC of the European Parliament and of the Council of 29 April 2004 on the protection of workers from the risks related to exposure to carcinogens or mutagens at work (Sixth individual Directive within the meaning of Article 16(1) Council Directive 89/391/EEC) (codified version) (OJ L 158, 30.4.2004). Off J Eur Union L 2004;229.Search in Google Scholar

75. Kiffmeyer T, Hadtstein C. Handling of chemotherapeutic drugs in the OR: hazards and safety considerations. Cancer Treat Res 2007;134:275-90. PMID: 1763306010.1007/978-0-387-48993-3_17Search in Google Scholar

76. Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Galichet L, Cogliano V; WHO International Agency for Research on Cancer Monograph Working Group. A review of human carcinogens - Part A: pharmaceuticals. Lancet Oncol 2009;10:13-4. doi: 10.1016/S1470-2045(08)70286-910.1016/S1470-2045(08)70286-9Open DOISearch in Google Scholar

77. International Agency for Research on Cancer (IARC). IARC Monographs, Chemical Agents and Related Occupations. Vol 100F (2012) [displayed 13 October 2017]. Available at http://monographs.iarc.fr/ENG/Monographs/vol100F/index.phpSearch in Google Scholar

78. Moretti M, Bonfiglioli R, Feretti D, Pavanello S, Mussi F, Grollino MG, Villarini M, Barbieri A, Ceretti E, Carrieri M, Buschini A, Appolloni M, Dominici L, Sabatini L, Gelatti U, Bartolucci GB, Poli P, Stronati L, Mastrangelo G, Monarca S. A study protocol for the evaluation of occupational mutagenic/carcinogenic risks in subjects exposed to antineoplastic drugs: a multicentric project. BMC Public Health 2011;11:195. doi: 10.1186/1471-2458-11-19510.1186/1471-2458-11-195307454621450074Open DOISearch in Google Scholar

79. Viegas S, Pádua M, Veiga AC, Carolino E, Gomes M. Antineoplastic drugs contamination of workplace surfaces in two Portuguese hospitals. Environ Monit Assess 2014;186:7807-18. doi: 10.1007/s10661-014-3969-110.1007/s10661-014-3969-125096642Open DOISearch in Google Scholar

80. Kopjar N, Garaj-Vrhovac V, Kašuba V, Rozgaj R, Ramić S, Pavlica V, Želježić D. Assessment of genotoxic risks in Croatian health care workers occupationally exposed to cytotoxic drugs: A multi-biomarker approach. Int J Hyg Environ Health 2009;212:414-31. doi: 10.1016/j.ijheh.2008.10.00110.1016/j.ijheh.2008.10.00119049854Open DOISearch in Google Scholar

81. Mahboob M, Rekhadevi P, Balasubramanyam A, Singh S, Rao Gs, Rahman M, Sailaja N, Prabhakar P, Reddy U, Grover P. Monitoring of oxidative stress in nurses occupationally exposed to antineoplastic drugs. Toxicol Int 2012;19:20-4. doi: 10.4103/0971-6580.9451010.4103/0971-6580.94510333924022736898Open DOISearch in Google Scholar

82. National Institute for Occupational Safety and Health (NIOSH). NIOSH Manual of Analytical Methods 4th Edition (2003-154) - 2004 [displayed 13 October 2017]. Available at https://www.cdc.gov/niosh/docs/2003-154/default.htmlSearch in Google Scholar

83. National Institute for Occupational Safety and Health (NIOSH). NIOSH Manual of Analytical Methods (NMAM) 5th Edition (2014-151) - 2016 [displayed 13 October 2017]. Available at https://www.cdc.gov/niosh/nmam/default.htmlSearch in Google Scholar

84. Meijster T, Fransman W, Veldhof R, Kromhout H. Exposure to antineoplastic drugs outside the hospital environment. Ann Occup Hyg 2006;50:657-64. doi: 10.1093/annhyg/mel023 85. Kiffmeyer TK, Tuerk J, Hahn M, Stuetzer H, Hadtstein C, Heinemann A, Eickmann U. Application and assessment of a regular environmental monitoring of the antineoplastic drug contamination level in pharmacies - the MEWIP project. Ann Occup Hyg 2013;57:444-55. doi: 10.1093/annhyg/mes08110.1093/annhyg/mel02385.KiffmeyerTK.aantineoplastic-theMEWIPproject.Hyg2013;57:444-55.doi:10.1093/annhyg/mes081Open DOISearch in Google Scholar

86. Meijster T, Fransman W, van Hemmen J, Kromhout H, Heederik D, Tielemans E. A probabilistic assessment of the impact of interventions on oncology nurses’ exposure to antineoplastic agents. Occup Environ Med 2006;63:530-7. doi: 10.1136/oem.2005.02272310.1136/oem.2005.022723Open DOISearch in Google Scholar

87. Kusnetz E, Condon M. Acute effects from occupational exposure to antineoplastic drugs in a para-professional health care worker. Am J Ind Med 2003;44:107-9. doi: 10.1002/ajim.1023010.1002/ajim.10230Open DOISearch in Google Scholar

88. Mader RM, Kokalj A, Kratochvil E, Pilger A, Rüdiger HW. Longitudinal biomonitoring of nurses handling antineoplastic drugs. J Clin Nurs 2009;18:263-9. doi: 10.1111/j.1365-2702.2007.02189.x10.1111/j.1365-2702.2007.02189.xOpen DOISearch in Google Scholar

89. El-Ebiary AA, Abuelfadl AA, Sarhan NI. Evaluation of genotoxicity induced by exposure to antineoplastic drugs in lymphocytes of oncology nurses and pharmacists. J Appl Toxicol 2013;33:196-201. doi: 10.1002/jat.173510.1002/jat.1735Open DOISearch in Google Scholar

90. Kromhout H, Hoek F, Uitterhoeve R, Huijbers R, Overmars RF, Anzion R, Vermeulen R. Postulating a dermal pathway for exposure to anti-neoplastic drugs among hospital workers. Applying a conceptual model to the results of three workplace surveys. Ann Occup Hyg 2000;44:551-60. PMID: 1104225810.1016/S0003-4878(00)00050-8Search in Google Scholar

91. Fransman W, Vermeulen R, Kromhout H. Occupational dermal exposure to cyclophosphamide in Dutch hospitals: a pilot study. Ann Occup Hyg 2004;48:237-44. doi: 10.1093/annhyg/meh01710.1093/annhyg/meh017Open DOISearch in Google Scholar

92. Laffon B, Teixeira JP, Silva S, Loureiro J, Torres J, Pásaro E, Méndez J, Mayan O. Genotoxic effects in a population of nurses handling antineoplastic drugs, and relationship with genetic polymorphisms in DNA repair enzymes. Am J Ind Med 2005;48:128-36. doi: 10.1002/ajim.2018910.1002/ajim.20189Open DOISearch in Google Scholar

93. Kolmodin-Hedman B, Hartvig P, Sorsa M, Falck K. Occupational handling of cytostatic drugs. Arch Toxicol 1983;54:25-33. PMID: 663935110.1007/BF00277812Open DOISearch in Google Scholar

94. Stücker I, Caillard JF, Collin R, Gout M, Poyen D, Hémon D. Risk of spontaneous abortion among nurses handling antineoplastic drugs. Scand J Work Environ Health 1990;16:102-7. PMID: 235319210.5271/sjweh.1811Open DOISearch in Google Scholar

95. Hedmer M, Tinnerberg H, Axmon A, Jönsson BAG. Environmental and biological monitoring of antineoplastic drugs in four workplaces in a Swedish hospital. Int Arch Occup Environ Health 2008;81:899-911. doi: 10.1007/s00420-007-0284-y10.1007/s00420-007-0284-y18066576Open DOISearch in Google Scholar

96. Chu WC, Hon C-Y, Danyluk Q, Chua PPS, Astrakianakis G. Pilot assessment of the antineoplastic drug contamination levels in British Columbian hospitals pre- and post-cleaning. J Oncol Pharm Pract 2012;18:46-51. doi: 10.1177/107815521140210610.1177/107815521140210621737485Open DOISearch in Google Scholar

97. Fransman W, Roeleveld N, Peelen S, de Kort W, Kromhout H, Heederik D. Nurses with dermal exposure to antineoplastic drugs. Epidemiology 2007;18:112-9. doi: 10.1097/01.ede.0000246827.44093.c110.1097/01.ede.0000246827.44093.c117099323Open DOISearch in Google Scholar

98. Stover D, Achutan C. Occupational exposures to antineoplastic drugs in an Oncology-Hematology Department. J Occup Environ Hyg 2011;8:D1-6. doi: 10.1080/15459624.2011.53751010.1080/15459624.2011.53751021154100Search in Google Scholar

99. Harrison BR, Peters BG, Bing MR. Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed-system drug transfer device versus standard preparation techniques. Am J Health Syst Pharm 2006;63:1736-44. doi: 10.2146/ajhp05025810.2146/ajhp05025816960258Open DOISearch in Google Scholar

100. Tompa A, Biró A, Jakab M. Genotoxic monitoring of nurses handling cytotoxic drugs. Asia Pac J Oncol Nurs 2016;3:365-9. doi: 10.4103/2347-5625.19648410.4103/2347-5625.196484521487028083554Open DOISearch in Google Scholar

101. Ladeira C. Human Biomonitoring: Biomarkers, Susceptibility, and Nutrigenetics. LAP LAMBERT Academic Publishing, 2015.Search in Google Scholar

102. Schierl R, Böhlandt A, Nowak D. Guidance values for surface monitoring of antineoplastic drugs in German pharmacies. Ann Occup Hyg 2009;53:703-11. doi: 10.1093/annhyg/ mep05010.1093/annhyg/mep05019620232Open DOISearch in Google Scholar

103. Cancer Nurses Society of Australia (CNSA). Position Statement on the Minimum Safety Requirements for Nurses involved in the Administration of Anti-Cancer Drugs within the Oncology and Non-Oncology Setting. Cancer Nurses Soc Aust 2013 [displayed 13 October 2017]. Available at https://www.eviq.org.au/getmedia/13df577c-f417-4951-a0d6-c18bc84407f1/newlogoApril-01-2c-2010-CNSA-NECMinimum-Safety-For-Nurses-re-Anti-Cancer-Drugs-Position-Statement-33b-1.pdf.aspxSearch in Google Scholar

104. Hon C-Y, Teschke K, Chua P, Venners S, Nakashima L. Occupational exposure to antineoplastic drugs: identification of job categories potentially exposed throughout the hospital medication system. Saf Health Work 2011;2:273-81. doi: 10.5491/SHAW.2011.2.3.27310.5491/.2011.2.3.273Open DOISearch in Google Scholar

105. Cavallo D, Ursini CL, Omodeo-Salè E, Iavicoli S. Micronucleus induction and FISH analysis in buccal cells and lymphocytes of nurses administering antineoplastic drugs. Mutat Res 2007;628:11-8. doi: 10.1016/j.mrgentox.2006.10.01410.1016/j.mrgentox.2006.10.01417223378Search in Google Scholar

106. Langford S, Fradgley F, Evans M, Blanks C. Assessing the risk of handling monoclonal antibodies. Hospital Pharmacist 2008;15:60-4.Search in Google Scholar

107. Clinical Oncology Society of Australia (COSA). Position Statement : Safe handling of monoclonal antibodies in healthcare settings, 2013 [displayed 13 October 2017]. Available at https://www.cosa.org.au/media/173517/cosacpg-handling-mabs-position-statement_-november-2013_final.pdfSearch in Google Scholar

108. Halsen G, Krämer I. Assessing the risk to health care staff from long-term exposure to anticancer drugs - the case of monoclonal antibodies. J Oncol Pharm Pract 2011;17:68-80. doi: 10.1177/107815521037684710.1177/107815521037684720667850Open DOISearch in Google Scholar

109. Heijink R, Koopmanschap M, Polder J. International comparison of cost of illness. Bilthoven: RIVM, Centre for Public Health Forecasting; 2006.Search in Google Scholar

110. Heijink R, Noethen M, Renaud T, Koopmanschap M, Polder J. Cost of illness: an international comparison. Australia, Canada, France, Germany and The Netherlands. Health Policy 2008;88:49-61. doi: 10.1016/j.healthpol.2008.02.01210.1016/j.healthpol.2008.02.01218407369Open DOISearch in Google Scholar

111. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 2011;103:117-28. doi: 10.1093/jnci/djq49510.1093/jnci/djq495310756621228314Search in Google Scholar

112. Dollinger M. Guidelines for hospitalization for chemotherapy. Oncologist 1996;1:107-11. PMID: 1038797510.1634/theoncologist.1-1-107Search in Google Scholar

113. Savoie ML, Nevil TJ, Song KW, Forrest DL, Hogge DE, Nantel SH, Shepherd JD, Smith CA, Sutherland HJ, Toze CL, Lavoie JC. Shifting to outpatient management of acute myeloid leukemia: a prospective experience. Ann Oncol 2006;17:763-8. doi: 10.1093/annonc/mdl01110.1093/annonc/mdl01116497826Search in Google Scholar

114. Summers N, Dawe U, Stewart DA. A comparison of inpatient and outpatient ASCT. Bone Marrow Transplant 2000;26:389-95. doi: 10.1038/sj.bmt.170253410.1038/sj.bmt.170253410982285Open DOISearch in Google Scholar

115. Glück S, des Rochers C, Cano C, Dorreen M, Germond C, Gill K, Lopez P, Sinoff C. High-dose chemotherapy followed by autologous blood cell transplantation: a safe and effective outpatient approach. Bone Marrow Transplant 1997;20:431-4. doi: 10.1038/sj.bmt.170090110.1038/sj.bmt.17009019313874Open DOISearch in Google Scholar

116. Beaty RS, Bernhardt MB, Berger AH, Hesselgrave JE, Russell HV, Okcu MF. Inpatient versus outpatient vincristine, dactinomycin, and cyclophosphamide for pediatric cancers: Quality and cost implications. Pediatr Blood Cancer 2015;62:1925-8. doi: 10.1002/pbc.2561010.1002/pbc.2561026152314Search in Google Scholar

117. Abro EU, Morris K, Hodges G, Butler JP, Curley C, Pillai ES, Kennedy GA. Outpatient administration of Hyper-CVAD chemotherapy for acute lymphoblastic leukaemia / lymphoma is safe and associated with similar toxicity compared to inpatient delivery. Blood 2013;122:5017.10.1182/blood.V122.21.5017.5017Search in Google Scholar

118. Vaughn JE, Othus M, Powell MA, Gardner KM, Rizzuto DL, Hendrie PC, Becker PS, Pottinger PS, Estey EH, Walter RB. Resource utilization and safety of outpatient management following intensive induction or salvage chemotherapy for acute myeloid leukemia or myelodysplastic syndrome: nonrandomized clinical comparative analysis. JAMA Oncol 2015;1:1120-7. doi: 10.1001/jamaoncol.2015.296910.1001/jamaoncol.2015.2969472098126355382Open DOISearch in Google Scholar

119. Gandhi TK, Bartel SB, Shulman LN, Verrier D, Burdick E, Cleary A, Rothschild JM, Leape LL, Bates DW. Medication safety in the ambulatory chemotherapy setting. Cancer 2005;104:2477-83. doi: 10.1002/cncr.2144210.1002/cncr.2144216245353Open DOISearch in Google Scholar

120. Fleissig A, Jenkins V, Catt S, Fallowfield L. Multidisciplinary teams in cancer care: are they effective in the UK? Lancet Oncol 2006;7:935-43. doi: 10.1016/S1470-2045(06)70940-810.1016/S1470-2045(06)70940-8Open DOISearch in Google Scholar